Filing Details
- Accession Number:
- 0001127602-22-018184
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-06-28 09:42:43
- Reporting Period:
- 2022-06-24
- Accepted Time:
- 2022-06-28 09:42:43
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 794172 | Meridian Bioscience Inc | VIVO | In Vitro & In Vivo Diagnostic Substances (2835) | 310888197 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1719325 | P. John Kenny | 3471 River Hills Drive Cincinnati OH 45244 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-06-24 | 13,559 | $10.10 | 278,690 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-24 | 13,559 | $30.00 | 265,131 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2022-06-27 | 61,437 | $10.10 | 326,568 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-06-27 | 61,437 | $30.39 | 265,131 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2022-06-24 | 13,559 | $0.00 | 13,559 | $10.10 |
| Common Stock | Stock Options (Right to Buy) | Disposition | 2022-06-27 | 61,437 | $0.00 | 61,437 | $10.10 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 127,476 | 2029-11-05 | No | 4 | M | Direct | |
| 66,039 | 2029-11-05 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
- The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.11. The Reporting Person undertakes to provide full pricing information if requested by the Securities andExchange Commission, the issuer or a security holder of the issuer.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
- The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.76. The Reporting Person undertakes to provide full pricing information if requested by the Securities andExchange Commission, the issuer or a security holder of the issuer.
- The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
- These non-qualified options were awarded under the 2012 Stock Incentive Plan pursuant to Mr. Kenny's Amended and Restated Employment Agreement effective October 1, 2019. The options vest on a pro rata basis over the three (3) years from the Agreement's effective date.
- The option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective November 15, 2021.
Billionaire Hedge Funds
